Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
0.7590
Dollar change
-0.0241
Percentage change
-3.08
%
Index- P/E- EPS (ttm)-1.17 Insider Own17.00% Shs Outstand61.77M Perf Week-2.06%
Market Cap45.44M Forward P/E- EPS next Y-0.66 Insider Trans0.57% Shs Float51.26M Perf Month30.41%
Income-68.80M PEG- EPS next Q-0.21 Inst Own43.41% Short Float3.23% Perf Quarter3.90%
Sales0.00M P/S- EPS this Y47.04% Inst Trans-15.26% Short Ratio3.03 Perf Half Y-27.71%
Book/sh1.18 P/B0.64 EPS next Y33.20% ROA-48.97% Short Interest1.66M Perf Year8.43%
Cash/sh1.42 P/C0.54 EPS next 5Y- ROE-69.15% 52W Range0.45 - 1.79 Perf YTD-24.85%
Dividend Est.- P/FCF- EPS past 5Y-46.23% ROI-72.57% 52W High-57.60% Beta1.45
Dividend TTM- Quick Ratio5.15 Sales past 5Y0.00% Gross Margin- 52W Low68.29% ATR (14)0.11
Dividend Ex-Date- Current Ratio5.15 EPS Y/Y TTM42.87% Oper. Margin- RSI (14)52.33 Volatility9.75% 18.51%
Employees58 Debt/Eq0.36 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq0.30 EPS Q/Q36.72% Payout- Rel Volume0.12 Prev Close0.78
Sales Surprise-100.00% EPS Surprise-33.74% Sales Q/Q- EarningsNov 13 BMO Avg Volume546.36K Price0.76
SMA206.74% SMA5016.42% SMA200-20.75% Trades Volume65,279 Change-3.08%
Date Action Analyst Rating Change Price Target Change
Nov-29-24Resumed Wedbush Outperform $3 → $4
Sep-03-24Initiated Rodman & Renshaw Buy $7
Mar-08-22Downgrade JP Morgan Overweight → Neutral
Jan-19-22Downgrade Goldman Buy → Neutral $29 → $6
Jul-01-21Initiated Raymond James Outperform $29
Jun-15-21Initiated BTIG Research Buy $25
Mar-04-21Upgrade Goldman Neutral → Buy $28 → $30
Feb-04-21Initiated Guggenheim Buy $25
Jan-25-21Initiated Wedbush Outperform $26
Jan-04-21Upgrade JP Morgan Neutral → Overweight $25 → $35
Nov-30-24 06:55AM
Nov-14-24 07:29AM
Nov-13-24 07:00AM
Nov-06-24 07:00AM
Oct-24-24 07:00AM
09:36PM Loading…
Sep-23-24 09:36PM
07:00AM
Sep-19-24 01:25AM
Sep-16-24 07:00AM
Sep-10-24 07:52AM
Aug-30-24 07:00AM
Aug-08-24 07:00AM
Aug-06-24 07:00AM
Aug-01-24 12:30PM
07:00AM
07:13AM Loading…
Jul-25-24 07:13AM
Jul-16-24 07:43AM
07:00AM
Jun-18-24 09:35AM
Jun-05-24 07:30AM
May-21-24 08:00AM
May-16-24 12:00PM
May-14-24 01:54PM
07:00AM
Apr-22-24 07:00AM
Mar-07-24 12:00PM
Mar-06-24 01:52PM
Mar-05-24 07:00AM
Mar-04-24 07:00AM
Feb-27-24 07:00AM
07:09PM Loading…
Feb-01-24 07:09PM
Jan-31-24 07:30AM
Dec-25-23 10:14PM
Dec-20-23 07:00AM
Nov-17-23 04:30PM
Nov-13-23 07:00AM
Oct-30-23 07:00AM
Oct-20-23 04:30PM
Sep-25-23 07:00AM
Aug-11-23 10:04AM
Aug-07-23 07:15AM
07:00AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jul-24-23 12:37PM
Jul-06-23 11:17AM
Jun-05-23 07:00AM
May-11-23 07:00AM
May-04-23 07:00AM
Apr-21-23 04:01PM
Apr-17-23 07:00AM
Mar-29-23 09:02AM
Mar-27-23 07:00AM
Mar-08-23 07:14AM
Mar-07-23 12:42AM
Mar-06-23 07:00AM
Mar-01-23 07:00AM
Feb-28-23 07:00AM
Feb-27-23 07:00AM
Feb-24-23 07:00AM
Feb-20-23 05:59PM
Feb-15-23 07:00AM
Jan-20-23 04:01PM
Jan-07-23 07:39AM
Dec-14-22 12:13PM
07:00AM
Nov-21-22 05:24AM
Nov-10-22 07:00AM
Nov-08-22 07:00AM
Nov-03-22 07:30AM
Oct-14-22 04:01PM
Oct-11-22 12:25PM
Oct-10-22 07:00AM
Sep-26-22 07:00AM
Aug-19-22 04:01PM
Aug-11-22 07:00AM
Aug-05-22 07:00AM
Aug-04-22 07:00AM
Jul-28-22 07:30AM
Jul-21-22 04:01PM
Jul-12-22 08:19AM
Jul-06-22 07:00AM
Jun-09-22 07:30AM
Jun-08-22 07:30AM
Jun-01-22 10:19AM
07:30AM
May-20-22 04:01PM
May-18-22 07:00AM
May-16-22 07:00AM
May-09-22 07:00AM
May-04-22 10:55AM
May-03-22 02:13PM
May-02-22 04:01PM
Apr-22-22 04:01PM
Mar-29-22 07:00AM
Mar-28-22 07:00AM
Mar-15-22 11:22AM
11:12AM
07:00AM
Mar-10-22 07:00AM
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORBIMED ADVISORS LLC10% OwnerDec 09 '24Sale0.8454,18145,5127,643,285Dec 11 05:32 PM
ORBIMED ADVISORS LLC10% OwnerDec 10 '24Sale0.808,0156,4127,635,270Dec 11 05:32 PM
ORBIMED ADVISORS LLC10% OwnerDec 11 '24Sale0.8080647,635,190Dec 11 05:32 PM
ORBIMED ADVISORS LLC10% OwnerDec 04 '24Sale0.7976,20060,1987,718,369Dec 06 07:07 PM
ORBIMED ADVISORS LLC10% OwnerDec 06 '24Sale0.8220,90317,1407,697,466Dec 06 07:07 PM
OrbiMed Private Investments VIStockholderDec 04 '24Proposed Sale0.892,985,5182,657,111Dec 04 07:03 PM
Worldwide Healthcare Trust PLCStockholderDec 04 '24Proposed Sale0.892,028,3071,805,193Dec 04 06:57 PM
Lynx1 Capital Management LP10% OwnerNov 25 '24Buy0.56259,998146,6658,686,953Nov 27 06:11 PM
Lynx1 Capital Management LP10% OwnerNov 26 '24Buy0.71167,055118,1918,854,008Nov 27 06:11 PM
Lynx1 Capital Management LP10% OwnerNov 27 '24Buy0.6729,30019,6638,883,308Nov 27 06:11 PM
ORBIMED ADVISORS LLC10% OwnerSep 19 '24Sale0.7139,30027,9037,794,569Sep 23 04:51 PM
ORBIMED ADVISORS LLC10% OwnerSep 17 '24Sale0.73111,40081,3227,859,500Sep 18 06:38 PM
ORBIMED ADVISORS LLC10% OwnerSep 16 '24Sale0.7463,10046,6947,970,900Sep 18 06:38 PM
ORBIMED ADVISORS LLC10% OwnerSep 18 '24Sale0.7325,63118,7117,833,869Sep 18 06:38 PM
Worldwide Healthcare Trust PLCOwnerSep 16 '24Proposed Sale0.81241,328194,752Sep 16 08:38 PM
OrbiMed Private Investments VIOwnerSep 16 '24Proposed Sale0.81927,572748,551Sep 16 08:36 PM
Borthwick KathleenSVP, INTERIM CFOFeb 13 '24Sale0.971,4701,42628,466Feb 13 07:36 PM
Forman Mark SCHIEF MEDICAL OFFICERFeb 13 '24Sale0.971,6381,58948,631Feb 13 07:34 PM
Forman Mark SChief Medical OfficerJan 02 '24Sale0.9115,81314,39045,269Jan 03 04:21 PM
Cale Edgar B.GC & Corporate SecretaryJan 02 '24Sale0.9115,81314,39045,995Jan 03 04:19 PM